Literature DB >> 8833919

Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a.

A Mathew1, I Kurane, A L Rothman, L L Zeng, M A Brinton, F A Ennis.   

Abstract

A severe complication of dengue virus infection, dengue hemorrhagic fever (DHF), is hypothesized to be immunologically mediated and virus-specific cytotoxic T lymphocytes (CTLs) may trigger DHF. It is also likely that dengue virus-specific CTLs are important for recovery from dengue virus infections. There is little available information on the human CD8+ T cell responses to dengue viruses. Memory CD8+CTL responses were analyzed to determine the diversity of the T cell response to dengue virus and to identify immunodominant proteins using PBMC from eight healthy adult volunteers who had received monovalent, live-attenuated candidate vaccines of the four dengue serotypes. All the donors had specific T cell proliferation to dengue and to other flaviviruses that we tested. CTLs were generated from the stimulated PBMC of all donors, and in the seven donors tested, dengue virus-specific CD8+CTL activity was demonstrated. The nonstructural (NS3 and NS1.2a) and envelope (E) proteins were recognized by CD8+CTLs from six, five, and three donors, respectively. All donors recognized either NS3 or NS1.2a. In one donor who received a dengue 4 vaccine, CTL killing was seen in bulk culture against the premembrane protein (prM). This is the first demonstration of a CTL response against the prM protein. The CTL responses using the PBMC of two donors were serotype specific, whereas all other donors had serotype-cross-reactive responses. For one donor, CTLs specific for E, NS1.2a, and NS3 proteins were all HLA-B44 restricted. For three other donors tested, the potential restricting alleles for recognition of NS3 were B38, A24, and/or B62 and B35. These results indicate that the CD8+CTL responses of humans after immunization with one serotype of dengue virus are diverse and directed against a variety of proteins. The NS3 and NS1.2a proteins should be considered when designing subunit vaccines for dengue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8833919      PMCID: PMC507603          DOI: 10.1172/JCI118964

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Peptide selection by class I molecules of the major histocompatibility complex.

Authors:  T Elliott; M Smith; P Driscoll; A McMichael
Journal:  Curr Biol       Date:  1993-12-01       Impact factor: 10.834

2.  Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a.

Authors:  B Falgout; R Chanock; C J Lai
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

Review 3.  Immunity and immunopathology in dengue virus infections.

Authors:  I Kurane; F E Ennis
Journal:  Semin Immunol       Date:  1992-04       Impact factor: 11.130

4.  Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population.

Authors:  M DiBrino; K C Parker; D H Margulies; J Shiloach; R V Turner; W E Biddison; J E Coligan
Journal:  Biochemistry       Date:  1995-08-15       Impact factor: 3.162

5.  Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones.

Authors:  S J Gagnon; W Zeng; I Kurane; F A Ennis
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 6.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

7.  Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers.

Authors:  K T McKee; W H Bancroft; K H Eckels; R R Redfield; P L Summers; P K Russell
Journal:  Am J Trop Med Hyg       Date:  1987-03       Impact factor: 2.345

8.  Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes.

Authors:  A L Rothman; I Kurane; C J Lai; M Bray; B Falgout; R Men; F A Ennis
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Authors:  I Kurane; D Hebblewaite; W E Brandt; F A Ennis
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

10.  Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.

Authors:  P G Livingston; I Kurane; L C Dai; Y Okamoto; C J Lai; R Men; S Karaki; M Takiguchi; F A Ennis
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

View more
  44 in total

1.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

2.  Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections.

Authors:  Cameron P Simmons; Tao Dong; Nguyen Vinh Chau; Nguyen Thi Phuong Dung; Tran Nguyen Bich Chau; Le Thi Thu Thao; Nguyen Thi Dung; Tran Tinh Hien; Sarah Rowland-Jones; Jeremy Farrar
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Sculpting the immunological response to dengue fever by polytopic vaccination.

Authors:  Hao Zhou; Michael W Deem
Journal:  Vaccine       Date:  2005-12-28       Impact factor: 3.641

4.  Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Authors:  Joseph D Comber; Aykan Karabudak; Xiaofang Huang; Paolo A Piazza; Ernesto T A Marques; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

6.  Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques.

Authors:  Katherine M Mladinich; Shari M Piaskowski; Richard Rudersdorf; Christopher M Eernisse; Kim L Weisgrau; Mauricio A Martins; Jessica R Furlott; Charalambos D Partidos; Joseph N Brewoo; Jorge E Osorio; Nancy A Wilson; Eva G Rakasz; David I Watkins
Journal:  Immunogenetics       Date:  2011-09-01       Impact factor: 2.846

Review 7.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

8.  Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection.

Authors:  A Mathew; I Kurane; S Green; H A Stephens; D W Vaughn; S Kalayanarooj; S Suntayakorn; D Chandanayingyong; F A Ennis; A L Rothman
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

9.  Antibody recognition of the dengue virus proteome and implications for development of vaccines.

Authors:  Stefan Fernandez; Emily D Cisney; Alexander P Tikhonov; Barry Schweitzer; Robert J Putnak; Monika Simmons; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

10.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.